Cervical Cancer
Conditions
Interventions
Experimental Group:TMMR tLND, without any adjuvant radiotherapy after surgery, and cisplatin monotherapy (50 mg/m2, 3 weeks apart, 6 cycles) in patients with high-risk factors
Control Group:In traditional RH, adjuvant chemoradiotherapy is present in patients with postoperative high-risk factors
Sponsors
Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18~60 years old; 2. Body mass index (BMI) =70; 6. Patients all signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Distant metastases other than para-aortic lymph nodes; 2. Pregnant women; 3. Receiving neoadjuvant chemotherapy or radiotherapy before surgery; 4. Patients with severe underlying diseases, immune diseases, mental illnesses or other malignant tumors; 5. Life expectancy of less than 6 months; 6. Unable to receive follow-up on schedule.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year and 5-year disease-free survival (DFS) rates;General clinical features; | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year and 5-year overall survival (OS) rates;Recurrence rate;Recurrence pattern; | — |
Countries
China
Contacts
Public ContactLi Xuqing
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed